Trevi Therapeutics, Inc. Forecasted to Post Q2 2023 Earnings of Per Share

TRVI Stock  USD 2.88  0.06  2.13%   
Under 58% of all Trevi Therapeutics' traders are looking to take a long position. The analysis of overall sentiment of trading Trevi Therapeutics stock suggests that some investors are interested at this time. Trevi Therapeutics' investing sentiment shows overall attitude of investors towards Trevi Therapeutics.
  
Trevi Therapeutics, Inc. Equities research analysts at SVB Leerink issued their Q2 2023 EPS estimates for shares of Trevi Therapeutics in a note issued to investors on Wednesday, February 8th. SVB Leerink analyst T. Smith forecasts that the company will post earnings of per share for the quarter. SVB

Read at thelincolnianonline.com
news
  

Trevi Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Trevi Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Trevi Therapeutics Fundamental Analysis

We analyze Trevi Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trevi Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trevi Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Trevi Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Trevi Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Trevi Therapeutics stock to make a market-neutral strategy. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics with similar companies.

Peers

Trevi Therapeutics Related Equities

ANTXAN2 Therapeutics   21.90   
0%
100.0%
CUECue Biopharma   11.93   
0%
54.0%
LYRALyra Therapeutics   10.53   
0%
48.0%
CCCCC4 Therapeutics   8.59   
0%
39.0%
PRLDPrelude Therapeutics   7.14   
0%
32.0%
CGEMCullinan Oncology   2.75   
0%
12.0%
FHTXFoghorn Therapeutics   2.57   
0%
11.0%
BCABBioatla   2.44   
0%
11.0%
BOLTBolt Biotherapeutics   1.59   
0%
7.0%
RZLTRezolute   1.00   
0%
4.0%
SPROSpero Therapeutics   0.88   
0%
4.0%
SEERSeer   0.81   
0%
3.0%
ANEBAnebulo Pharmaceuticals   0.70   
0%
3.0%
ORICOric Pharmaceuticals   0.70   
3.0%
0%
TARAProtara Therapeutics   0.99   
4.0%
0%
CHRSCoherus BioSciences   3.17   
14.0%
0%

Complementary Tools for Trevi Stock analysis

When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance